Richard Alan Moller

Array ( [id] => 18595995 [patent_doc_number] => 20230270786 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA [patent_app_type] => utility [patent_app_number] => 18/175347 [patent_app_country] => US [patent_app_date] => 2023-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53743 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18175347 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18595995 [patent_doc_number] => 20230270786 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA [patent_app_type] => utility [patent_app_number] => 18/175347 [patent_app_country] => US [patent_app_date] => 2023-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53743 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18175347 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19173778 [patent_doc_number] => 20240159752 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => METHODS FOR COLORECTAL CANCER DIAGNOSIS AND PROGNOSIS [patent_app_type] => utility [patent_app_number] => 18/171399 [patent_app_country] => US [patent_app_date] => 2023-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14659 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 359 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18171399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18657728 [patent_doc_number] => 20230303678 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => METHODS FOR TREATMENT OF SUBJECTS WITH PLAQUE PSORIASIS OF THE SCALP [patent_app_type] => utility [patent_app_number] => 18/158767 [patent_app_country] => US [patent_app_date] => 2023-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34896 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18158767 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19551072 [patent_doc_number] => 12134771 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-05 [patent_title] => Fusion protein and use thereof in base editing [patent_app_type] => utility [patent_app_number] => 18/150778 [patent_app_country] => US [patent_app_date] => 2023-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 16 [patent_no_of_words] => 15334 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18150778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18307058 [patent_doc_number] => 20230110958 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => IL27 RECEPTOR AGONISTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/887565 [patent_app_country] => US [patent_app_date] => 2022-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57934 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17887565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895204 [patent_doc_number] => 20240010689 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => CHIMERIC KLEBICINS [patent_app_type] => utility [patent_app_number] => 17/811492 [patent_app_country] => US [patent_app_date] => 2022-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15758 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17811492 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18077377 [patent_doc_number] => 20220402989 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => IL2-BASED THERAPEUTICS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/806566 [patent_app_country] => US [patent_app_date] => 2022-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27824 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -68 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17806566 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18077377 [patent_doc_number] => 20220402989 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => IL2-BASED THERAPEUTICS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/806566 [patent_app_country] => US [patent_app_date] => 2022-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27824 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -68 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17806566 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19969701 [patent_doc_number] => 12338293 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-24 [patent_title] => UPAR antibodies and fusion proteins with the same [patent_app_type] => utility [patent_app_number] => 17/702329 [patent_app_country] => US [patent_app_date] => 2022-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 24 [patent_no_of_words] => 31861 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 263 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17702329 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18210010 [patent_doc_number] => 20230056271 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => NOVEL DARPin BASED MULTI-SPECIFIC T-CELL ENGAGERS [patent_app_type] => utility [patent_app_number] => 17/654209 [patent_app_country] => US [patent_app_date] => 2022-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 91790 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17654209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17828415 [patent_doc_number] => 20220265719 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => IMMUNOTHERAPIES [patent_app_type] => utility [patent_app_number] => 17/675294 [patent_app_country] => US [patent_app_date] => 2022-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71481 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17675294 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17960042 [patent_doc_number] => 20220340622 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => RECOMBINANT HAGFISH PROTEINS AND FIBERS [patent_app_type] => utility [patent_app_number] => 17/651020 [patent_app_country] => US [patent_app_date] => 2022-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13381 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17651020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19738351 [patent_doc_number] => 12215169 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-04 [patent_title] => Anti-complement C1s antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/556061 [patent_app_country] => US [patent_app_date] => 2021-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 4 [patent_no_of_words] => 64628 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17556061 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19667556 [patent_doc_number] => 12180284 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-31 [patent_title] => Clinical methods for use of a PD-L1-binding molecule comprising a Shiga toxin effector [patent_app_type] => utility [patent_app_number] => 17/553333 [patent_app_country] => US [patent_app_date] => 2021-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 28 [patent_no_of_words] => 45337 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17553333 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17704641 [patent_doc_number] => 20220204647 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/548135 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49815 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17548135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18844525 [patent_doc_number] => 20230406929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => POLYPEPTIDE CONSTRUCTS BINDING TO CD3 [patent_app_type] => utility [patent_app_number] => 18/251120 [patent_app_country] => US [patent_app_date] => 2021-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70122 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 267 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18251120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17426934 [patent_doc_number] => 20220054642 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => SUPRAMOLECULAR MODIFICATION OF PROTEINS [patent_app_type] => utility [patent_app_number] => 17/517111 [patent_app_country] => US [patent_app_date] => 2021-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36554 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -76 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17517111 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879121 [patent_doc_number] => 20240002490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => USE OF ANTI-PRO/LATENT MYOSTATIN ANTIBODY FOR TREATING SPINAL MUSCULAR ATROPHY [patent_app_type] => utility [patent_app_number] => 18/250489 [patent_app_country] => US [patent_app_date] => 2021-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 94878 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250489 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879121 [patent_doc_number] => 20240002490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => USE OF ANTI-PRO/LATENT MYOSTATIN ANTIBODY FOR TREATING SPINAL MUSCULAR ATROPHY [patent_app_type] => utility [patent_app_number] => 18/250489 [patent_app_country] => US [patent_app_date] => 2021-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 94878 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250489 [rel_patent_id] =>[rel_patent_doc_number] =>)